:

Department of Research Programs > CancerCenterClinicalTrials
 
Cancer Center Clinical Trials

Research Study for Individuals with Amputations
Official Title:Study to Identify the Genetic Variations Associated with Phantom Limb Pain
Date Window: 6/12/2014 - 12/31/2014
Contact for Details:monica.l.tung.ctr@health.mil or (301) 456-5941
Summary:​We are recruiting individuals with amputations to participate in a study to determine the underlying causes of phantom limb pain (PLP). You may participate if you are an adult over age 18 with an amputation of any level, regardless of whether or not you have PLP. 

Study participation can be completed in a single, 30 minute visit including a questionnaire and a 2-Tbsp blood draw. You may not participate if you have a disease, condition, or are taking medications that would increase your risk during the blood draw. We compensate $50 for participation.


RESTORE
Official Title:Restorative Exercise and Strength Training for Operational Resilience and Excellence
Date Window: 12/9/2013 - 12/31/2014
Contact for Details:RESTORE Team restore@dvpmi.org or 301-816-4731
Summary:​We are seeking volunteers with low back pain to participate in the RESTORE research study.  If you have had chronic low back pain for greater than 3 months and are DEERS eligible, then you may qualify to participate in this study.

This is a randomized study.  Participants may receive individualized treatment sessions that focuses on core strength, balance,  flexibility, and relaxation to help manage low back pain.  All participants will receive compensation for participating in the study.  Contact us for more information.

The purpose of the study is to learn the effectiveness of integrative therapies on chronic or recurrent low back pain.  The Defense and Veterans Center for Integrative Pain Management (DVCIPM) will be conducting this research intervention at WRNMMC.  COL Chester Buckenmaier III, MD is the Principal Investigator


Radiation Therapy to the Whole Breast after Lumpectomy for Early-Stage Breast Cancer in Larger Dose/Fewer Treatment versus Standard Treatment
Official Title:RTOG 1005: A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer
Date Window: 8/4/2013 - 8/4/2018
Contact for Details:Jean A. Petrov, RN MS (301) 295-5010; Kathleen A. Noel, RN MS (301) 400-0507
Summary:​The purpose of this study is to compare two groups given whole breast radiation therapy after  lumpectomy.  Group I will be given daily standard whole breast radiation followed by a daily "boost" (additional radiation) dose extending treatment up to 6 1/2 weeks.  Group II will be given a higher daily dose together with a daily "boost" dose over 3 weeks.

http:/www.ClinicalTrials.gov (NCT0149322


Imaging in Combat Veterans with Blast Injury and Posttraumatic Stress Disorder
Official Title:The ViRTICo-BP Trials: Virtual Reality Therapy and Imaging in Combat Veterans with Blast Injury and Posttraumatic Stress Disorder
Date Window: 2/27/2007 - 12/31/2015
Contact for Details:Patricia Taylor, (240) 507 6339, patricia.taylor.ctr@usuhs.edu
Summary:The main purpose of this study is to determine whether functional magnetic resonance imaging (fMRI), can distinguish between service members with and without traumatic brain injury (TBI), as well as those with posttraumatic stress disorder (PTSD) who receive either virtual reality exposure therapy (VRET) or "usual care" for their PTSD. We have previously shown in another study that exposure therapy significantly improves function in the brain, and we are now trying to see if this effect is unique to exposure therapy, or also occurs with other treatments. We have also seen links between structural changes in the brain in those with traumatic brain injury (TBI), and brain function as measured by fMRI,  and in turn with PTSD symptoms. However, we need to confirm these findings in larger numbers, and also hope to see whether there is something significantly different about those who have PTSD after TBI vs. those in whom it does not follow a TBI.

Enhancing Exposure Therapy for PTSD
Official Title:Enhancing Exposure Therapy for PTSD: Virtual Reality and Imaginal Exposure with a Cognitive Enhancer
Date Window: 8/7/2011 - 7/26/2015
Contact for Details:Patricia Taylor, (240) 507 6339, patricia.taylor.ctr@usuhs.edu
Summary:This is a randomized controlled trial in which everyone receives active treatment for combat-related Post Traumatic Stress Disorder (PTSD) that has good evidence to support it, directly comparing virtual reality exposure therapy (VRE) and prolonged imaginal exposure therapy (PE), to determine which is better. There is also a second randomization so that, whether an individual is getting VRE or PE, they will also receive either D-Cycloserine (DCS) or placebo. DCS is a drug that has been FDA approved for over 50 years to treat some infections, and which, at a much lower, very safe dose, we think might help people respond better to treatment for PTSD. 

Do you continue to experience PTSD symptoms with your current medication?
Official Title:Riluzole for PTSD: Efficacy of a Glutamatergic Modulator as Augmentation Treatment for Posttraumatic Stress Disorder
Date Window: 10/1/2013 - 5/15/2015
Contact for Details:Patricia Spangler, Ph.D., 240-620-4076
Summary:​The purpose of the study is to evaluate the efficacy of riluzole in OIF/OEF/OND veterans (age 18-65) with PTSD, with or without mild traumatic brain injury, who have responded sub-optimally to other medications. Active duty personnel are eligible for monetary compensation

GOG 0263
Official Title:GOG 0263: Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery
Date Window: 9/18/2013 - 9/18/2018
Contact for Details:Karen Harrington, karen.m.harrington.civ@health.mil
Summary:This randomized phase III trial is studying giving radiation therapy together with chemotherapy to see how well it works compared to radiation therapy alone in treating patients with stage I or stage II cervical cancer who previously underwent surgery.

Active Comparator: Arm I: Patients undergo pelvic EBRT or IMRT once daily, 5 days a week, for 5½ weeks.

 

Experimental: Arm II: Patients receive cisplatin IV over 1-2 hours on day 1 and undergo radiotherapy as in Arm I. Treatment with cisplatin repeats every 7 days for up to 6 weeks in the absence of disease progression or unacceptable toxicity.


GOG 0274
Official Title:GOG 0274: Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
Date Window: 9/18/2013 - 9/18/2018
Contact for Details:Karen Harrington (karen.m.harrington.civ@health.mil)
Summary:This randomized phase III trial studies how well giving cisplatin and radiation therapy together with or without carboplatin and paclitaxel works in treating patients with locally advanced cervical cancer.

Active Comparator: Arm I: Patients receive cisplatin IV over 60-90 minutes on days 1, 8, 15, 22, and 29. Patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate, pulsed-dose rate, or low-dose rate intracavitary brachytherapy.

Experimental: Arm II: Patients receive cisplatin and undergo external-beam radiation and brachytherapy as in arm I. Beginning 4 weeks later, patients also receive adjuvant chemotherapy comprising paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.


GOG 0261
Official Title:GOG 0261: Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine or Ovarian Cancer
Date Window: 9/18/2013 - 9/18/2018
Contact for Details:Karen Harrington (karen.m.harrington.civ@health.mil)
Summary:This randomized phase III trial is studying giving paclitaxel together with carboplatin to see how well it works compared with giving paclitaxel together with ifosfamide in treating patients with newly diagnosed persistent or recurrent uterine or ovarian cancer.

Experimental: Arm I:  Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1.

Experimental: Arm II:  Patients receive paclitaxel as in arm I and ifosfamide IV over 1 hour on days 1-3.


GOG 0258
Official Title:GOG 258: Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer
Date Window: 9/18/2013 - 9/19/2018
Contact for Details:Karen Harrington (karen.m.harrington.civ@health.mil)
Summary:This randomized phase III trial is studying carboplatin and paclitaxel to see how well they work when given with or without cisplatin and radiation therapy in treating patients with stage I, stage II, stage III, or stage IVA endometrial cancer.

Experimental: Arm I:  Patients receive cisplatin IV on days 1 and 29. Patients also undergo external-beam radiotherapy once daily, 5 days a week, for 5-6 weeks. Some patients may then undergo brachytherapy over 2-3 weeks. Beginning within 8 weeks after completion of chemoradiotherapy, patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
 
Experimental: Arm II:  Patient receive paclitaxel IV over 3 hours and carboplatin IV on day 1.  Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
 
 


1 - 10 Next

Contact

Location
Building 17B
3rd Floor, Suite E

Phone
Main (301) 295-8239/8219

Hours of Operation
Monday thru Friday
0700 - 1630